Opthea Has Completed Enrollment In COAST Phase 3 Trial Of Sozinibercept Plus Aflibercept For Wet Age-related Macular Degeneration. Enrollment In ShORe Study Is Expected To Be Completed In Q2 2024, Topline Data From Both Trials Are Expected By Mid-2025

2/14/24 6:17:17 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OPT alert in real time by email

Get the next $OPT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPT

Date	Price Target	Rating	Analyst
12/8/2022	$14.00	Buy	H.C. Wainwright
4/26/2022	$25.00	Outperform	SVB Leerink

More analyst ratings

$OPT
Leadership Updates

Live Leadership Updates

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with
10/8/24 7:00:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical
7/17/24 7:15:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024. Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team. Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- an
4/8/24 6:42:02 PM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$OPT
Press Releases

Fastest customizable press release news feed in the world

Opthea to Participate in November Investor Conferences
Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024. Conference details are as follows: Bell Potter Healthcare ConferencePresentation:Monday, November 18, 2024, 3:00 PM AEDT (Virtual)Presenter:Frederic Guerard, Phar
11/4/24 7:00:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea Files Notice of Annual General Meeting
Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea's innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the filing of the Notice of the Annual General Meeting and Explanatory Notes distributed to shareholders for the Company's annual general meeting to
10/16/24 7:00:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. David Boyer, MD, will present an update on Opthea's wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity
10/10/24 7:30:00 AM ET
$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Opthea Has Completed Enrollment In COAST Phase 3 Trial Of Sozinibercept Plus Aflibercept For Wet Age-related Macular Degeneration. Enrollment In ShORe Study Is Expected To Be Completed In Q2 2024, Topline Data From Both Trials Are Expected By Mid-2025

Chat with this insight

Recent Analyst Ratings for
$OPT

$OPT
Leadership Updates

Live Leadership Updates

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

Opthea Appoints John Han, PharmD, as VP Medical Affairs

$OPT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Opthea Limited

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

$OPT
Press Releases

Fastest customizable press release news feed in the world

Opthea to Participate in November Investor Conferences

Opthea Files Notice of Annual General Meeting

Opthea Wet AMD Program to be Presented at Innovate Retina

$OPT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Opthea Ltd. with a new price target

SVB Leerink initiated coverage on Opthea Ltd. with a new price target

$OPT
SEC Filings

$OPT
Financials

Live finance-specific insights

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

$OPT
Market Insights

Live Market Insights

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

12 Health Care Stocks Moving In Friday's Pre-Market Session

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

Opthea Has Completed Enrollment In COAST Phase 3 Trial Of Sozinibercept Plus Aflibercept For Wet Age-related Macular Degeneration. Enrollment In ShORe Study Is Expected To Be Completed In Q2 2024, Topline Data From Both Trials Are Expected By Mid-2025

Chat with this insight

Recent Analyst Ratings for $OPT

$OPT Leadership Updates

Live Leadership Updates

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

Opthea Appoints John Han, PharmD, as VP Medical Affairs

$OPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Opthea Limited

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

$OPT Press Releases

Fastest customizable press release news feed in the world

Opthea to Participate in November Investor Conferences

Opthea Files Notice of Annual General Meeting

Opthea Wet AMD Program to be Presented at Innovate Retina

$OPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Opthea Ltd. with a new price target

SVB Leerink initiated coverage on Opthea Ltd. with a new price target

$OPT SEC Filings

$OPT Financials

Live finance-specific insights

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

$OPT Market Insights

Live Market Insights

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

12 Health Care Stocks Moving In Friday's Pre-Market Session

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

Recent Analyst Ratings for
$OPT

$OPT
Leadership Updates

$OPT
Large Ownership Changes

$OPT
Press Releases

$OPT
Analyst Ratings

$OPT
SEC Filings

$OPT
Financials

$OPT
Market Insights